Cybin Inc. is a biopharmaceutical company that is developing psychedelic-based therapeutics to treat a range of mental health disorders. The company's product pipeline includes CYB003, CYB004, and CYB005, which are designed to treat major depressive disorder, anxiety disorders, and neuroinflammation, respectively. Based in Toronto, Canada, Cybin Inc. has also developed EMBARK, a breakthrough psychedelic-assisted psychotherapy.